Background/Aims-A major drawback of
Patients/Methods-Sixty seven patients with inoperable oesophageal or gastric cardia cancers and satisfactory swallowing after initial laser recanalisation were randomised to palliative external beam radiotherapy (30 Gy in 10 fractions) or no radiotherapy. All patients underwent a 'check' endoscopy five weeks after initial recanalisation and were subsequently reendoscoped only for recurrent dysphagia, which occurred in 59 patients.
Results-Dysphagia was relieved equally well in both groups and the improvement was maintained with further endoscopic treatment. The initial dysphagia controlled interval and the duration between procedures required to maintain lifelong palliation (treatment interval) increased from five to nine weeks (median) in the radiotherapy group (p<0.01 both parameters). Radiotherapy was well tolerated in all but three patients. One perforation occurred and two fistulae opened after dilatation in patients who received radiotherapy.
Conclusion-Additional radiotherapy reduces the necessity for therapeutic endoscopy for a patient's remaining life. It has an important role in relatively well patients who are likely to survive long enough to benefit. (Gut 1997; 40: 362-369)
The most common and distressing symptomatic problem for patients with oesophageal and gastric cardia cancer is profound dysphagia. This has several major consequences including cachexia, local discomfort and aspiration pneumonia. Laser treatment offers rapid relief of the dysphagia, can often be performed as an outpatient procedure and does not have systemic effects. Serious complications are rare. The major drawback is the need for repeated treatments every five weeks or so, to maintain good swallowing. Although laser is effective at tumour debulking, disease is inevitably left in the oesophageal wall and beyond the lumen in local nodes; tumour regrowth usually occurs fairly rapidly. Radiotherapy, however, has the potential for treating the whole oesophageal tumour and the local regional draining sites,' and thus should be complementary to laser treatment.
External beam radiotherapy alone relieves dysphagia slowly, often taking several weeks for maximal effect.2 Palliative radiotherapy may prolong survival in patients with comparatively good swallowing at presentation but does less well in those who are not swallowing well initially.3 There is thus both theoretical and clinical evidence to support the concept that a patient whose swallowing has been improved by laser recanalisation should benefit further from radiotherapy. There have, however, only been a few studies' that have investigated the combination of laser and radiotherapy, and intraluminal (brachytherapy) rather than external beam radiotherapy has generally been used. Bader4 also gave external beam treatment to those with squamous cell cancers. Brachytherapy causes more superficial damage to the tumour as there is a rapid fall off in dose with distance from the source, and is not generally as effective in terms of irradiating the whole tumour depth (and length) as external beam treatment. These studies did, however, report prolonged dysphagia-free intervals, although only the first was randomised and the benefit was limited to patients with squamous cell cancers.
A pilot study from our unit,7 using palliative external beam radiotherapy, a more widely available and practical technique than brachytherapy, showed an encouraging reduction in the frequency of follow up therapeutic endoscopies compared with laser treatment alone. This randomised study was initiated to discover whether palliative external beam radiotherapy at the dose which causes minimal distress to these seriously ill patients may reduce the need for frequent follow up therapeutic endoscopies compared with laser treatment alone.
Methods

PATIENT SELECTION
The patients entered into this study were recruited from patients presenting at or referred to University College Hospital London between January 1990 and May 1992. Patients with predominantly exophytic carcinomas of the oesophagus and gastric cardia thought suitable for laser treatment were eligible. All patients recruited were deemed inoperable because of advanced disease or unacceptable anaesthetic risk. Twenty seven had squamous cell carcinomas of the oesophagus and 40 adenocarcinomas of the cardia. None had previously received radiotherapy or chemotherapy. Patients with malignancy arising in organs other than the oesophagus or gastric cardia and causing dysphagia by direct invasion or metastatic spread were excluded.
Dysphagia was graded as in our previous publications (O=normal; 1 =most solids; 2= semi-solids; 3=liquids only; 4=difficulty with liquids). Patients with dysphagia scores of 3 or worse after maximal laser treatment were considered unsuitable for study. Such patients were intubated as this subgroup had not done well with radiotherapy in the pilot study. Abdominal ultrasound was performed in all patients and 59 underwent intra-oesophageal endoluminal ultrasound after initial laser recanalisation.
Twenty four (36%) patients were over 75 years, a figure comparable with that for the overall incidence of these cancers in England and Wales but higher than in other hospital series.8 Table I shows the demographic data according to randomisation. The distribution of patient characteristics in the two groups was very similar. Fourteen had documented metastatic disease and 13 known advanced local disease (four detected at computed tomography scan, two unresectable at laparotomy, and all 13 endoscopically large tumours, of which 12 were subsequently found to be stage 4 tumours on endoluminal ultrasound). The remaining 40 patients were considered unsuitable for surgery because of age or general debility, or both, or coexistent medical conditions (mainly cardiopulmonary) which were considered to confer an unacceptable surgical risk. Eight of these 40 (four in each arm) had anastomotic recurrences.
ESTIMATION OF SAMPLE SIZE
Sample size was estimated using data from the pilot study. This was to ascertain the number of patients required in the study to detect a worthwhile effect, if it exists, and to be reasonably sure that no benefit exists if it is not detected. The parameter we chose to assess was the time from 'check' endoscopy to the next therapeutic procedure (initial dysphagia- The data on 42 patients in whom paired data are available were compared using the Wilcoxon signed rank test (before and after treatment for each arm). No significant differences were found. Twenty two of these patients (10 undergoing radiotherapy) required laser before ultrasound to permit probe passage.
S) PATIENTS WITH BULKY TUMOURS AND METASTASES
Nineteen patients had bulky tumours at initial endoluminal ultrasound (>2 cm wall thickness). Sixteen of these had radiologically malignant nodes and seven had known distant metastases. The tumour length in this group was greater than the rest of the patients in the study ( Patients with squamous cell cancers who received radiotherapy were more likely to develop predominantly fibrous strictures (10/14 v 3/11 who received laser only) and treatment of such strictures resulted in the opening up of fistulae in two patients (see later).
In all, 25 patients required oesophageal prostheses a median of 13 weeks (range 0-60 weeks) after 'check' endoscopy. Fourteen had received radiotherapy and 11 had not. Twenty four were used in patients who had difficulty managing a semi-solid diet for most of the time. Sixteen of these had troublesome extrinsic strictures and eight intraluminal tumour that was no longer adequately controlled with laser. Standard Celestin prostheses were used in all but three of these patients who received cuffed Wilson Cooke tubes. These three had tight strictures which developed after radiotherapy. Two developed fistulae (one oesophagobronchial, one oesophagopleural) and one a perforation after dilatation. Both fistulae occurred in elderly female patients with squamous cell cancers, one cervical and one lower thoracic, and both died shortly after intubation. Two of these patients, including one with a fistula, developed the complication within a few weeks of radiotherapy. The other fistula occurred late (20 weeks after radiotherapy). One The ultrasound suggested malignant lymphadenopathy in 75% of these patients (T4 tumours). Such patients are incurable even if fit for surgery (or radical radiotherapy) and have been appropriately selected for palliative therapy. Three of 13 (23%) patients with nodes >1 cm in the radiotherapy group showed a partial response (node size reduced by 50% or more). Overall, there was no statistically significant change in wall thickness or node size at 'check' endoscopy in either arm of the study. There was, however, a trend toward a reduction in node size in the radiotherapy group and an increase in node size in the laser only group but these differences were not significant. The measurements of oesophageal wall thickness must be treated with some caution in view of the necessity to perform examinations immediately after laser treatment in many cases. It is disappointing that the macroscopic effect of a dose of 30 Gy external beam radiotherapy on local tumour seems limited, but this is only a palliative dose, and a full assessment of its effect would require serial ultrasound examinations in both groups throughout their survival. In a previous study from this unit,'2 a number of patients did not swallow well despite apparently adequate laser recanalisation. This was ascribed to pseudoachalasia in patients with bulky cardia tumours. It is interesting that six of 11 The survival data in this randomised study show a similar spectrum regardless of the treatment arm. If patients with metastases and large tumours are excluded, the median survival is identical in both groups. It is worth noting, however, that two patients with adenocarcinomas of the cardia who received radiotherapy survived for long periods (76 and 98 weeks). This prolonged survival is seen as a tail on the survival curve. Both were elderly women and had neither bulky tumours (>2 cm thick) nor metastases at presentation, but otherwise had no clear characteristics different from the rest of the group.
It is disappointing that a more definitive difference in survival did not emerge in view of the results in the pilot study. However, the main aim of giving radiotherapy in addition to laser was to prolong the dysphagia controlled interval and length of survival is a secondary concern in this group of patients.
Comparatively few complications occurred, though it is of concern that the major ones were in patients undergoing radiotherapy. This may be partly because of the tendency for tight fibrous strictures to develop in patients with squamous cell cancers treated with external beam radiotherapy. It is important to be aware of the potential for this problem as extra care during dilatation may avert it. Intubation was performed late in patients in whom the preferred treatment was unsuccessful and the relative lack of complications for such procedures was encouraging. The only two treatment related deaths occurred in patients who had known fistulae after dilatation.
Overall, these results suggest an average of only one therapeutic endoscopy saved per patient by the use of external beam radiotherapy; however, in those who live longer, two or more procedures may not be necessary. On the basis of these results, it is unlikely that external beam radiotherapy would benefit most patients undergoing palliation for malignant dysphagia, but it could be argued that additional palliative external beam radiotherapy (at the doses used) is worthwhile for selected patients who are inoperable and who do not have bulky disease or metastases. In particular, those who are relatively fit but may have to travel long distances for each treatment might prefer a single more lengthy admission to hospital at the start of treatment. Such patients are likely to live long enough to benefit. Perhaps more importantly this study has shown that external beam radiotherapy in addition to laser is capable of prolonging the dysphagia controlled interval. This effect might be further improved by addition of local endooesophageal radiotherapy (brachytherapy) or regimens for internal radiotherapy that provide higher doses in a smaller number of fractions which can be administered more rapidly, and without prolonged hospitalisation.
Other endoscopic techniques for relieving swallowing such as alcohol injection or BICAP probe have also been shown to be partially effective in the palliation of malignant dysphagia.'3 14 It is likely that the benefit of dual modality radiotherapy in combination with laser would be mirrored for such techniques and appropriate studies with these combinations should be encouraged.
